- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
drkoop buys drDrew to reach teen market
drkoop buys drDrew to reach teen marketdrkoop.com has bought drDrew.com, a healthcare content Web site targeting the 14- to 24-year-old market, for 1.58 million shares in common stock and $150,000 cash. Through the acquisition, which brings
drkoop buys drDrew to reach teen market
drkoop.com has bought drDrew.com, a healthcare content Web site targeting the 14- to 24-year-old market, for 1.58 million shares in common stock and $150,000 cash. Through the acquisition, which brings drkoop's user base to some two million, drkoop hopes to drive additional licensing revenue and leverage this access to the teen/young adult audience. While drDrew.com will continue to operate as a separate site, the two sites will integrate some content. The acquisition was not a risky move for the beleaguered dot-com and drkoop will continue to evaluate acquiring "undervalued properties," said Ed Cespedes, president of drkoop.
- Search Again
- Return To HNN Homepage
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
